Get the Stockscreener App
35.93
1.43%
-0.52
After Hours:
36.16
0.23
+0.64%
Exelixis Inc stock is traded at $35.93, with a volume of 1.73M.
It is down -1.43% in the last 24 hours and up +28.92% over the past month.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$36.45
Open:
$36.45
24h Volume:
1.73M
Relative Volume:
0.85
Market Cap:
$10.21B
Revenue:
$2.08B
Net Income/Loss:
$466.92M
P/E Ratio:
126.83
EPS:
0.2833
Net Cash Flow:
$404.94M
1W Performance:
+3.69%
1M Performance:
+28.92%
6M Performance:
+74.67%
1Y Performance:
+66.27%
1-Day Range:
$35.57
$36.73
1-Week Range:
$34.40
$36.73
52-Week Range:
$19.20
$36.73
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
35.93 | 10.21B | 2.08B | 466.92M | 404.94M | 0.2833 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis to Present at Piper Sandler and Citi Healthcare Conferences in December | EXEL Stock News - StockTitan
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December - The Bakersfield Californian
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion - Yahoo Finance
Exelixis reiterates Equal Weight rating, stock target amid FDA update By Investing.com - Investing.com Canada
Exelixis reiterates Equal Weight rating, stock target amid FDA update - Investing.com
Massachusetts Financial Services Co. MA Decreases Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Zacks Investment Ideas feature highlights: InterDigital, Futu and Exelixis - Yahoo Finance
Exelixis EVP Haley Patrick J. sells $352,700 in stock - Investing.com
FDA to Review Exelixis' Application to Expand Use of Cancer Drug - MarketWatch
Exelixis Cancer Drug CABOMETYX Faces FDA Advisory Committee Review for Tumor Treatment | EXEL Stock News - StockTitan
Exelixis stock hits 52-week high at $36.6 amid robust growth By Investing.com - Investing.com South Africa
Connor Clark & Lunn Investment Management Ltd. Makes New $1.97 Million Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis stock hits 52-week high at $36.6 amid robust growth - Investing.com Nigeria
Exelixis Stock Surges 25% in a Month: Time to Buy or Sell? - MSN
Neuroendocrine Tumors Market to Showcase Rapid Growth During the Study Period (2020–2034), at a CAGR of 5.1%| DelveInsight - GlobeNewswire Inc.
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Landscape Capital Management L.L.C. Takes $721,000 Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Holdings Raised by Victory Capital Management Inc. - MarketBeat
Intech Investment Management LLC Buys 75,489 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
GSA Capital Partners LLP Has $304,000 Stock Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
FY2024 EPS Estimates for Exelixis Raised by Zacks Research - MarketBeat
Navellier & Associates Inc. Takes Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Stake Lowered by Commerce Bank - MarketBeat
Kidney Cancer Drugs Market Huge Growth in Future Scope 2024-2031 - openPR
Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online
3 Reasons Growth Investors Will Love Exelixis (EXEL) - Yahoo Finance
Ontario Teachers Pension Plan Board Reduces Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
EULAV Asset Management Lowers Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Thyroid Cancer Therapeutics Market May See a Big Move| Pfizer, Exelixis, AbbVie - openPR
Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity - Yahoo Finance
Exelixis exec Haley Patrick sells $1.43 million in stock By Investing.com - Investing.com Australia
Exelixis exec Haley Patrick sells $1.43 million in stock - Investing.com
Janney Montgomery Scott LLC Decreases Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Seizert Capital Partners LLC - MarketBeat
1 No-Brainer Stock to Buy With $40 - AOL
Cornercap Investment Counsel Inc. Trims Stock Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
18,300 Shares in Exelixis, Inc. (NASDAQ:EXEL) Bought by Entropy Technologies LP - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Receives $31.44 Consensus Target Price from Analysts - MarketBeat
Principal Financial Group Inc. Decreases Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - MSN
CWA Asset Management Group LLC Invests $577,000 in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Here's Why Exelixis (EXEL) is a Strong Value Stock - MSN
What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now? - MSN
Here is Why Growth Investors Should Buy Exelixis (EXEL) Now - MSN
Los Angeles Capital Management LLC Has $46.47 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Van ECK Associates Corp Boosts Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Have Insiders Sold Exelixis Shares Recently? - Simply Wall St
Exelixis CSO Aftab Dana sells $3.39 million in stock - Investing.com
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November - BioSpace
Exelixis CSO Aftab Dana sells $3.39 million in stock By Investing.com - Investing.com UK
Exelixis to shed 212K sf of industrial in Alameda - The Real Deal
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):